Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey
Purpose: This noninterventional, cross-sectional survey estimated the prevalence and consequences of residual disease in apremilast-treated US adults with moderate to severe psoriasis. Materials and Methods: Residual disease was defined as experiencing moderate, severe, or very severe psoriasis over...
Saved in:
| Main Authors: | Tina Bhutani, Sayeli Jayade, Sanika Rege, Hannah Penton, Vardhaman Patel, Samaneh Kalirai, Daniel Wolin, Kimberly Boyle, Lauren Seigel |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2366532 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Successful treatment by deucravacitinib of psoriasis refractory to apremilast
by: Shigeki Inui, et al.
Published: (2025-06-01) -
Assessing the Effect of Apremilast on Serum Leptin levels in Obese Patients with Psoriasis
by: Haitham Mohammed Saad, et al.
Published: (2024-12-01) -
THE EFFICACY AND SAFETY OF THE NEW DRUG APREMILAST FOR THE TREATMENT OF PSORIASIS AND PSORIATIC ARTHRITIS
by: Yu. L. Korsakova, et al.
Published: (2016-12-01) -
Cost per response analysis of deucravacitinib versus apremilast and first-line biologics among patients with moderate to severe plaque psoriasis in the United States
by: Sang Hee Park, et al.
Published: (2024-12-01) -
Expression dynamics of cytokine genes is related to the apremilast treatment effectiveness in patients with severe psoriasis
by: Dmitry A. Verbenko, et al.
Published: (2024-03-01)